Physician profile
Arun P Patel
NPI 1205815255
$5,823.32
in general payments reported to CMS, 2019-2025
37 companies · $1,109 in 2025
The $1,109 reported for 2025 was more than what 91% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $940 · 2020: $631 · 2021: $1,090 · 2022: $679 · 2023: $581 · 2024: $794 · 2025: $1,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,484.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $991.19 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $869.71 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $594.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $434.75 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $272.48 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $256.84 | 2022-2025 | Rexulti, Nuedexta |
| Merck Sharp & Dohme LLC | $256.53 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.10 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $209.77 | 2020-2022 | |
| Lundbeck LLC | $166.26 | 2023-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $156.94 | 2020-2021 | |
| Pfizer INC. | $153.25 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $139.05 | 2019-2025 | |
| Amgen INC. | $133.73 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $98.86 | 2022-2025 | Caplyta |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $98.39 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $93.01 | 2022-2024 | |
| Abbvie INC. | $59.18 | 2021-2025 | |
| Nestle Healthcare Nutrition INC. | $51.24 | 2021-2022 | |
| Edwards Lifesciences Corporation | $49.10 | 2020-2023 | Sapien 3 Ultra Resilia |
| Sanofi-Aventis U.S. LLC | $47.07 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $44.04 | 2019 | |
| Mylan Specialty L.P. | $43.16 | 2021-2022 | |
| Organogenesis INC. | $38.86 | 2019 | |
| Boston Scientific Corporation | $38.33 | 2022-2025 | Watchman Flx |
| Phathom Pharmaceuticals, INC. | $37.21 | 2024 | Voquezna |
| Xeris Pharmaceuticals, INC. | $33.66 | 2022-2024 | Keveyis |
| Astellas Pharma US INC | $33.08 | 2023-2024 | Veozah |
| Grifols USA, LLC | $32.46 | 2019 | |
| Eisai INC. | $20.40 | 2021 | |
| Gilead Sciences, INC. | $19.88 | 2023 | |
| Inspire Medical Systems, INC. | $19.45 | 2025 | Inspire |
| Almatica Pharma LLC | $17.85 | 2022 | |
| Paratek Pharmaceuticals, INC. | $17.09 | 2024 | Nuzyra |
| Sumitomo Pharma America, INC. | $16.83 | 2024 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $13.52 | 2021 | |
| Kyowa Kirin, INC. | $11.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arun Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.